Intellectual Property

Seropeutics holds broad intellectual property rights to both the SERx – 500 and SERx – 400 series with multiple issued patents, applications and anticipated filings.

University of Florida IP: 3 Families

  • Patents/Patent Applications Based on PCT/US2008/007458
    • Patents covering methods of treatment with genus of SERx – 400 series granted in US, Europe and Japan. Further application pending in US with composition claims. Life of patents is to 2028 (clinical trial extension to 2031)
  • Patent Applications Based on PCT/US2008/007457:
    • Covers SERx – 500 series compounds; Natural life of patents is to 2028; Allowable composition claims in US
  • Patent/Patent Applications Based on PCT/US2010/00133:
    • Natural life of patents is to 2030; Granted in US with claims to a genus of SERx – 400 series. Applications pending in US, Europe, and Japan.

Northeastern University IP: 2 Families

  • Applications to be filed from PCT/US15/31523
    • Discloses specific SERx – 500 series lead compounds,  animal studies confirming utility, as well as uses of SERx – 500 series to treat stereotypy. Can be nationalized broadly in Q4, 2016. Life of patents is 2035
  • Applications to be filed from US Provisional 62/163,652
    • Discloses further compounds with specific biodistribution features for GI pathologies. Can be nationalized broadly in Q4, 2017. Natural life of patents is to 2036.